Chimeron Bio is at the forefront of advancing genetic medicine through its innovative technologies, particularly focusing on self-amplifying RNA (saRNA) and a proprietary delivery platform known as ChaESAR™. This platform enables the development of enhanced in vivo CAR-T therapies, which allow for direct administration of treatments into patients, streamlining the process and reducing costs. The technology is designed to achieve superior gene expression and therapeutic potency, making it suitable for a range of applications in oncology, including immuno-oncology and cancer vaccines. Chimeron Bio's approach also allows for the co-delivery of multiple RNA payloads, enhancing the potential for complex therapeutic strategies.

In addition to its CAR-T therapies, Chimeron Bio is developing cancer vaccines that aim to activate the patient's immune system to target and eliminate cancer cells. The company's unique multiplex nanoparticle technology facilitates the delivery of multiple genes, which can transform the tumor microenvironment and improve treatment outcomes. This versatile platform is not only applicable to oncology but also extends to infectious diseases and genetic disorders, positioning Chimeron Bio as a key player in the next generation of RNA therapeutics.

United States

Chimeron Bio is a biotechnology company focused on developing personalized gene therapies, including self-amplifying RNA vaccines and therapeutics designed on its proprietary technology.

Cancer

Genetic Diseases

Infectious Diseases

Chimeron Bio

Chimeron Drug#1 (self-amplifying RNA (saRNA) vaccines & therapeutics)

Biologics

Gene Therapy

Philadelphia, Pennsylvania, United States

Pennsylvania

CAR-T Immunotherapy

Cell Therapies

Immuno-Oncology

Personalized Medicine

RNA Therapies

Vaccines

Viral Therapies/Virotherapies

Therapeutic

Chimeron Bio

Company Details